Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market to Reach $7.5 Billion by 2030
The global market for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment estimated at US$2.8 Billion in the year 2022, is projected to reach a revised size of US$7.5 Billion by 2030, growing at a CAGR of 13.1% over the analysis period 2022-2030. Medication, one of the segments analyzed in the report, is projected to record 11% CAGR and reach US$4.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Other Treatments segment is readjusted to a revised 18.3% CAGR for the next 8-year period.The U.S. Market is Estimated at $816.7 Million, While China is Forecast to Grow at 12.6% CAGR
The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market in the U.S. is estimated at US$816.7 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 12.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11% and 11% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 9.3% CAGR.Select Competitors (Total 42 Featured) -
- Achillion Pharmaceuticals
- Akari Therapeutics
- Alexion Pharmaceuticals
- Amgen Inc.
- Apellis Pharmaceuticals
- F. Hoffmann-La Roche AG.
- GE Healthcare
- Johnson & Johnson
- Ra Pharmaceuticals
- Regeneron Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited (Shire Plc)
- Thermo Fisher Scientific Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its 'bumpy' reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
REST OF EUROPE
ASIA-PACIFIC
REST OF WORLD
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Achillion Pharmaceuticals
- Akari Therapeutics
- Alexion Pharmaceuticals
- Amgen Inc.
- Apellis Pharmaceuticals
- F. Hoffmann-La Roche AG.
- GE Healthcare
- Johnson & Johnson
- Ra Pharmaceuticals
- Regeneron Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited (Shire Plc)
- Thermo Fisher Scientific Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 93 |
Published | May 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 2.8 Billion |
Forecasted Market Value ( USD | $ 7.5 Billion |
Compound Annual Growth Rate | 13.1% |
Regions Covered | Global |